NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

Core Insights - NewAmsterdam Pharma is set to present additional safety and efficacy data from pivotal Phase 3 trials at the 2025 AHA Scientific Sessions, highlighting its focus on oral, non-statin medicines for cardiovascular disease patients [1][4] Group 1: Upcoming Presentations - The company will present a pooled analysis of the BROOKLYN and BROADWAY Phase 3 clinical trials, focusing on the effects of CETP inhibition with obicetrapib on LDL particles [2] - A digital poster presentation will discuss the combination of obicetrapib with ezetimibe on atorvastatin and its effects on atherosclerotic plaque lesions in specific mouse models [2] Group 2: Investor Conferences - NewAmsterdam management will participate in several investor conferences, including a fireside chat at the Guggenheim Annual Healthcare Innovation Conference on November 11, 2025 [3] - Additional fireside chats are scheduled at the Stifel Healthcare Conference on November 12, 2025, and the Jefferies London Healthcare Conference on November 19, 2025 [3] Group 3: Company Overview - NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing therapies for metabolic diseases, particularly targeting LDL-C levels in patients at risk of cardiovascular disease [4] - The company is investigating obicetrapib, a low-dose CETP inhibitor, as a potential adjunct therapy to statins for patients who do not respond well to existing treatments [4]